Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Teva Pharmaceutical Industries Ltd Stock Research

TEVA

10.00USD-0.20(-1.96%)Delayedas of 02 Oct 2023, 03:44 pm
Watchlist

Market Summary

USD10.00-0.20
Delayedas of 02 Oct 2023, 03:44 pm
-1.96%

TEVA Alerts

TEVA Stock Price

TEVA RSI Chart

TEVA Valuation

Market Cap

11.4B

Price/Earnings (Trailing)

-5.12

Price/Sales (Trailing)

0.76

EV/EBITDA

-9.99

Price/Free Cashflow

9.74

TEVA Price/Sales (Trailing)

TEVA Profitability

EBT Margin

-15.76%

Return on Equity

-20.38%

Return on Assets

-3.69%

Free Cashflow Yield

10.27%

TEVA Fundamentals

TEVA Revenue

Revenue (TTM)

15.0B

Revenue Y/Y

2.43%

Revenue Q/Q

5.93%

TEVA Earnings

Earnings (TTM)

-2.2B

Earnings Y/Y

-271.98%

Earnings Q/Q

-320.98%

Price Action

52 Week Range

7.0911.45
(Low)(High)

Last 7 days

-1.5%

Last 30 days

5.3%

Last 90 days

35.5%

Trailing 12 Months

30.4%

TEVA Financial Health

Current Ratio

1.1

TEVA Investor Care

Shares Dilution (1Y)

0.90%

Diluted EPS (TTM)

-2

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for TEVA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-08-07
Kalif Eliyahu Sharon
sold
-341,889
9.7335
-35,125
evp, chief financial officer
2023-08-04
Zaks Tal Zvi
acquired
-
-
15,810
-
2023-08-04
BARER SOL J
acquired
-
-
28,162
-
2023-08-04
Crane Rosemary A
acquired
-
-
15,810
-
2023-08-04
Satchi-Fainaro Ronit
acquired
-
-
15,810
-
2023-08-04
Vergis Janet S.
acquired
-
-
15,810
-
2023-08-04
LIEBERMAN GERALD M
acquired
-
-
15,810
-
2023-08-04
Elstein Amir
acquired
-
-
15,810
-
2023-08-04
Nisen Perry
acquired
-
-
15,810
-
2023-08-04
Weiss Amir
sold
-19,657
9.921
-1,981
chief accounting officer

1–10 of 50

Which funds bought or sold TEVA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-26
BROOKFIELD Corp /ON/
reduced
-72.04
-2,948,150
920,219
-%
2023-09-21
Baystate Wealth Management LLC
unchanged
-
-528
3,012
-%
2023-09-21
Jefferies Group LLC
reduced
-6.16
14,688
2,087,420
0.02%
2023-09-20
BARCLAYS PLC
reduced
-41.25
-7,900,000
7,898,000
-%
2023-09-12
Farther Finance Advisors, LLC
added
80.00
917
2,643
-%
2023-09-07
ST GERMAIN D J CO INC
new
-
279
279
-%
2023-08-24
Alberta Investment Management Corp
unchanged
-
-157,212
896,823
0.01%
2023-08-23
WOLVERINE TRADING, LLC
added
21.94
63,907
1,446,910
-%
2023-08-23
Stonebridge Capital Advisors LLC
unchanged
-
-132
753
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-0.16
-1,560,640
8,806,170
0.01%

1–10 of 44

Latest Funds Activity

Are funds buying TEVA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TEVA
No. of Funds

Schedule 13G FIlings of Teva Pharmaceutical Industries

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 09, 2023
capital research global investors
0.0%
0
SC 13G/A
Feb 13, 2023
capital research global investors
10.3%
114,793,989
SC 13G/A
Feb 11, 2022
capital research global investors
12.0%
132,350,750
SC 13G/A
Feb 16, 2021
capital research global investors
11.9%
130,140,247
SC 13G/A
Feb 03, 2021
wellington management group llp
0.03%
310,793
SC 13G/A
Feb 14, 2020
capital research global investors
11.9%
130,950,677
SC 13G/A
Feb 05, 2020
franklin resources inc
1.8%
19,916,016
SC 13G/A
Jan 28, 2020
wellington management group llp
7.43%
81,123,996
SC 13G

Recent SEC filings of Teva Pharmaceutical Industries

View All Filings
Date Filed Form Type Document
Sep 28, 2023
8-K
Current Report
Sep 05, 2023
3
Insider Trading
Sep 05, 2023
4
Insider Trading
Aug 24, 2023
8-K
Current Report
Aug 10, 2023
3
Insider Trading
Aug 10, 2023
4
Insider Trading
Aug 09, 2023
4
Insider Trading
Aug 07, 2023
4
Insider Trading
Aug 07, 2023
4
Insider Trading
Aug 07, 2023
4
Insider Trading

Peers (Alternatives to Teva Pharmaceutical Industries)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
483.3B
29.5B
-1.98% 63.22%
74.38
16.37
1.53% 14.16%
404.7B
97.8B
-4.87% -4.04%
31
4.14
2.29% -28.92%
272.8B
58.3B
-6.59% 20.44%
17.88
4.63
2.00% -81.24%
187.3B
77.9B
-7.60% -24.24%
8.72
2.4
-23.04% -26.74%
150.1B
45.2B
-6.96% -18.45%
23.72
3.25
-4.15% 20.34%
MID-CAP
6.5B
-
1.99% 679.20%
-74.1
4.1K
-86.94% 71.24%
4.3B
4.6B
-10.37% -11.13%
-63.85
0.93
6.60% 42.04%
SMALL-CAP
1.6B
627.1M
-7.75% -16.43%
-1.08
2.5
-0.20% -204.67%
1.5B
634.0M
-13.76% -17.16%
34.51
2.36
0.62% -24.59%
847.3M
244.3M
0.39% 9.53%
4.3
3.47
-39.50% -4.99%
762.2M
109.5M
6.95% -31.74%
-5.31
6.96
-2.66% -32.13%
484.8M
31.2M
-8.67% -53.78%
-4.6
15.55
407.54% -26.47%
430.9M
453.3M
72.08% -71.84%
-0.35
0.95
-16.04% 55.90%
248.8M
54.6M
-18.44% -38.79%
-2.74
4.56
9.39% -179.16%
-
2.2B
- -
-
-
-22.39% 63.59%

Teva Pharmaceutical Industries News

Digital Journal
Hospital Asset Management Market Present Scenario and Growth ....
Digital Journal,
88 minutes ago
Digital Journal
Globes

Returns for TEVA

Cumulative Returns on TEVA

-11.2%


10-Year Cumulative Returns

-18.9%


7-Year Cumulative Returns

-13.9%


5-Year Cumulative Returns

4.9%


3-Year Cumulative Returns

Risks for TEVA

What is the probability of a big loss on TEVA?

100%


Probability that Teva Pharmaceutical Industries stock will be more than 20% underwater in next one year

91.2%


Probability that Teva Pharmaceutical Industries stock will be more than 30% underwater in next one year.

37.7%


Probability that Teva Pharmaceutical Industries stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TEVA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Teva Pharmaceutical Industries was unfortunately bought at previous high price.

Drawdowns

Financials for Teva Pharmaceutical Industries

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue0.6%15,018,000,00014,926,000,00014,925,000,00015,142,000,00015,434,000,00015,558,000,00015,878,000,00016,233,000,00016,324,000,00016,284,000,00016,659,000,00016,673,000,00016,788,000,00017,095,000,00016,887,000,00016,838,000,00017,130,000,00017,505,000,00018,272,000,00019,251,000,00020,483,000,000
Gross Profit0.0%6,817,000,0006,815,000,0006,973,000,0007,253,000,0007,378,000,0007,457,000,0007,594,000,0007,593,000,0007,651,000,0007,541,000,0007,726,000,0007,636,000,0007,614,000,0007,744,000,0007,537,000,0007,550,000,0007,697,000,0007,837,000,0008,296,000,0008,769,000,0009,391,000,000
  S&GA Expenses0.4%2,237,000,0002,228,000,0002,265,000,0002,348,000,0002,406,000,0002,427,000,0002,429,000,0002,480,000,0002,488,000,0002,470,000,0002,498,000,0002,521,000,0002,511,000,0002,580,000,0002,614,000,0002,706,000,0002,810,000,0002,826,000,0002,916,000,0002,769,000,0002,913,000,000
  R&D Expenses-------------------114,000,00054,000,000229,000,000
EBITDA100.0%--116,000,000-809,000,000--594,000,0001,712,000,0002,879,000,000---1,794,000,000-1,948,000,000-2,182,000,0002,017,000,0001,286,000,0001,279,000,000-2,005,000,000-1,865,000,000-1,236,000,000166,000,000-9,554,000,000-9,169,000,000
EBITDA Margin100.0%--0.01-0.05--0.040.110.18---0.11-0.12-0.130.120.070.07-0.12-0.11-0.070.01-0.49-0.44
Interest Expenses---948,000,000---913,000,000---846,000,000---840,000,000---815,000,000--
Earnings Before Taxes10.5%-2,107,000,000-2,353,000,000-3,065,000,000-2,140,000,000-1,924,000,000-456,000,000658,000,000971,000,000-3,870,000,000-4,229,000,000-4,406,000,000-4,582,000,000-415,000,000-1,214,000,000-1,265,000,000-4,613,000,000-4,534,000,000-3,934,000,000-2,596,000,000-12,417,000,000-12,085,000,000
EBT Margin100.0%--0.16-0.21-0.14-0.12-0.030.040.06-0.24-0.26-0.26-0.27-0.02-0.07-0.07-0.27-0.26-0.22-0.14-0.63-0.58
Net Income-39.4%-2,233,000,000-1,602,000,000-2,353,000,000-1,290,000,000-1,054,000,000-615,000,000417,000,000726,000,000-3,915,000,000-3,982,000,000-3,990,000,000-4,030,000,0005,000,000-824,000,000-998,000,000-3,994,000,000-3,888,000,000-3,375,000,000-2,150,000,000-10,799,000,000-9,996,000,000
Net Income Margin100.0%--0.11-0.16-0.09-0.07-0.040.030.04-0.24-0.24-0.24-0.240.00-0.05-0.06-0.23-0.22-0.19-0.11-0.55-0.48
Free Cashflow-100.0%-964,000,0001,042,000,000514,000,000476,000,000585,000,000236,000,00088,000,000-131,000,000-94,000,000638,000,000902,000,000894,000,000413,000,000223,000,000-42,000,00084,000,000449,000,0001,795,000,0002,233,000,0002,534,000,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-0.8%43,09543,45644,00644,25245,93247,05947,66647,85149,19549,00450,64049,73754,99155,33057,47057,24659,42459,85460,68365,06167,030
  Current Assets5.1%12,08811,50112,05111,45312,16412,45112,57312,15412,82212,40113,00512,16012,78112,88413,46412,54213,80513,43113,79413,88114,711
    Cash Equivalents22.7%2,6692,1762,8012,2252,0582,2502,1982,0452,4361,7432,1771,8272,4021,8041,9751,2412,1651,9731,7821,8751,861
  Inventory-0.2%4,1094,1183,8333,8594,0494,0123,8184,1674,3624,4064,4034,5164,3614,2904,4224,6364,8504,7824,7314,8664,971
  Net PPE-0.7%5,7125,7515,7395,5685,7405,9325,9826,0406,1276,1126,2966,1526,1226,2216,4366,6436,7326,7856,8687,1017,213
  Goodwill-3.8%17,11817,79917,63318,43318,83719,98620,04020,17920,42120,30220,62420,22824,61624,49024,84624,65724,91324,82224,91727,58527,648
Liabilities1.6%35,38734,84435,31534,73436,10336,79936,42236,40037,88438,02939,57939,14540,16740,74242,40742,32244,17344,03344,88945,92747,662
  Current Liabilities13.8%11,84310,41111,46911,53410,99611,61311,02711,82512,69112,08913,16412,10311,75112,32213,67414,10714,45214,02814,32214,83014,215
Shareholder's Equity-18.1%7,0528,6127,8978,7679,82810,26011,24411,45111,31110,97511,06110,59214,82414,58815,06314,92515,25115,82115,79419,13419,368
  Retained Earnings-6.6%-13,950-13,086-12,882-11,660-11,716-11,484-10,529-10,370-10,662-10,869-10,946-11,096-6,747-6,887-6,956-7,066-6,752-6,063-5,958-3,072-2,864
  Additional Paid-In Capital0.1%27,74827,71927,68827,65227,62527,58727,56127,52927,50327,47427,44327,40327,37427,34227,31227,29327,25827,23427,21023,40423,426
Shares Outstanding0.4%1,1201,115-1,1111,1101,107-1,1031,1031,099-1,0961,0961,093-1,0921,0921,090-1,0181,018
Minority Interest-12.6%6567517947517919169669849879751,0359999721,0571,0911,1341,1281,0891,0871,4041,430
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations13.5%1,6951,4941,5901,0731,0591,1547986734515061,2161,4231,4419417485776731,0622,4462,9383,312
  Share Based Compensation-6.8%123132124121122112119124127130129111117115119132142159155149135
Cashflow From Investing18.2%7986756567338741,1761,5231,4181,2871,1198631,1521,2191,3351,3559991,1221,0991,8663,7043,461
Cashflow From Financing12.9%-1,912-2,195-1,487-1,277-2,014-1,677-2,172-1,796-1,676-1,678-1,885-2,001-2,405-2,437-1,926-2,184-1,428-1,449-3,351-5,358-5,478
  Dividend Payments-------------------12.0099.00222

TEVA Income Statement

2023-06-30
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Net revenues$ 3,878$ 3,786$ 7,539$ 7,447
Cost of sales2,0821,9924,1613,913
Gross profit1,7961,7943,3783,534
Research and development expenses240228473453
Selling and marketing expenses6035941,1491,178
General and administrative expenses307313602609
Intangible assets impairments6351241199
Goodwill impairment700745700745
Other assets impairments, restructuring and other items100118195246
Legal settlements and loss contingencies4627296951,854
Other income(33)(34)(34)(87)
Operating income (loss)(646)(949)(644)(1,662)
Financial expenses, net268211528468
Income (loss) before income taxes(914)(1,160)(1,172)(2,131)
Income taxes (benefit)(16)(900)(35)(899)
Share in (profits) losses of associated companies, net(1)0(1)(21)
Net income (loss)(898)(259)(1,136)(1,211)
Net income (loss) attributable to non-controlling interests(35)(27)(68)(24)
Net income (loss) attributable to Teva$ (863)$ (232)$ (1,068)$ (1,187)
Earnings (loss) per share attributable to ordinary shareholders:    
Basic$ (0.77)$ (0.21)$ (0.96)$ (1.07)
Diluted$ (0.77)$ (0.21)$ (0.96)$ (1.07)
Weighted average number of shares (in millions):    
Basic1,1201,1101,1181,109
Diluted1,1201,1101,1181,109

TEVA Balance Sheet

2023-06-30
Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 2,669$ 2,801
Accounts receivables, net of allowance for credit losses of $87 million and $91 million as of June 30, 2023 and December 31, 20223,5393,696
Inventories4,1093,833
Prepaid expenses1,2281,162
Other current assets486549
Assets held for sale5610
Total current assets12,08812,051
Deferred income taxes1,5781,453
Other non-current assets443441
Property, plant and equipment, net5,7125,739
Operating lease right-of-use assets, net418419
Identifiable intangible assets, net5,7386,270
Goodwill[1]17,11817,633
Total assets43,09544,006
Current liabilities:  
Short-term debt1,9802,109
Sales reserves and allowances3,4333,750
Accounts payables2,5081,887
Employee-related obligations451566
Accrued expenses2,4982,151
Other current liabilities9731,005
Total current liabilities11,84311,469
Long-term liabilities:  
Deferred income taxes534548
Other taxes and long-term liabilities3,9733,847
Senior notes and loans18,69819,103
Operating lease liabilities338349
Total long-term liabilities23,54323,846
Commitments and contingencies, see note 10
Total liabilities35,38735,315
Teva shareholders' equity:  
Ordinary shares of NIS 0.10 par value per share; June 30, 2023 and December 31, 2022: authorized 2,495 million shares; issued 1,227 million shares and 1,217 million shares, respectively.5757
Additional paid-in capital27,74827,688
Accumulated deficit(13,950)(12,882)
Accumulated other comprehensive loss(2,677)(2,838)
Treasury shares as of June 30, 2023 and December 31, 2022: 106 million ordinary shares(4,128)(4,128)
Stockholders' equity attributable to Teva shareholders7,0527,897
Non-controlling interests656794
Total equity7,7088,691
Total liabilities and equity$ 43,095$ 44,006
[1]Accumulated goodwill impairment as of June 30, 2023 and December 31, 2022 was approximately $27.6 billion.
KÃ¥re Schultz
37500
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.